| 306) osis and could help to develop an optimal treatment approach by an early detection. |
| 307) de effect profile of these AEDs, a recent treatment approach involves priority use o |
| 308) as the potential to inform a personalized treatment approach. |
| 309) Adropin treatment or transgenic adropin overexpres |
| 310) To date, there is no confirmed treatment or vaccine prevention strategy a |
| 311) today, there is no universal dengue fever treatment or vaccines unreservedly recomme |
| 312) f factors that are associated with poorer treatment outcome and inform the developme |
| 313) atment levels of perceived life stress on treatment outcome in a sample of 200 indiv |
| 314) ing blood is a significant factor for the treatment outcome in patients with locally |
| 315) udies published to date and difference in treatment protocols for TF-CBT used with p |
| 316) Development of treatment protocols specific to children w |
| 317) and caring and also on the use of medical treatment protocols. |
| 318) are an effective alternative to inpatient treatment that lead to sustained improveme |
| 319) For high-risk patients, the treatment that minimizes the risk of relap |
| 320) sent the hope for a new direction for HIV treatment that reduces adherence barriers |
| 321) Little is known about how the amount of treatment a person with aphasia receives i |
| 322) g signals for iron at 4 and 12 days after treatment, a significant decrease in peak |
| 323) physiology, pathophysiology, and disease treatment as they relate to gynecologic ma |
| 324) mbiont-free strain obtained by antibiotic treatment as well as genome analyses revea |
| 325) rofile followed by 2 weeks of either Epi treatment at 1 mg/kg/day by gavage (n = |
| 326) veloped for evaluating only one candidate treatment at a time, and are thus not opti |
| 327) he Bayesian posterior probability of each treatment being optimal. |
| 328) HNC) are diagnosed worldwide with primary treatment being surgery and radiotherapy. |
| 329) The average difference in post-treatment compared to pre-treatment non-HD |
| 330) high Drug Burden Index (DBI) polypharmacy treatment compared to control on physical |
| 331) on administration, hygiene and isolation, treatment decisions, or invasive procedure |
| 332) To improve dengue triage and treatment decisions, the WHO recommends cl |
| 333) aying reward responsiveness to accelerate treatment development for neuropsychiatric |
| 334) ions and laboratory animals, which hamper treatment development. |
| 335) Moreover, statin treatment did not reduce the number of flo |
| 336) Importantly, statin treatment did not reverse d-flow-regulated |
| 337) Treatment dose (amount of treatment) has b |
| 338) or post-stroke aphasia and to explore how treatment dose is conceptualized, measured |
| |